Prediction of efficacy for conversion from adjunctive therapy to monotherapy with eslicarbazepine acetate 800 mg once daily for partial-onset epilepsy

PURPOSE: Eslicarbazepine acetate (ESL) is a once-daily (QD) oral antiepileptic drug (AED) indicated for partial-onset seizures (POS). Clinical studies of gradual conversion to ESL 1,200 and 1,600 mg QD monotherapies were previously conducted in patients with POS who were not well-controlled by 1 or...

Descripción completa

Detalles Bibliográficos
Autores principales: Sunkaraneni, Soujanya, Passarell, Julie A, Ludwig, Elizabeth A, Fiedler-Kelly, Jill, Pitner, Janet K, Grinnell, Todd A, Blum, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5500545/
https://www.ncbi.nlm.nih.gov/pubmed/28721105
http://dx.doi.org/10.2147/CPAA.S133815

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5500545/
https://www.ncbi.nlm.nih.gov/pubmed/28721105
http://dx.doi.org/10.2147/CPAA.S133815

Ejemplares similares